Shenwan Hongyuan Group Co., Ltd. has released a research report stating that PDRN (Polydeoxyribonucleotide), with its reparative and anti-inflammatory effects, is another rising star in the field of regenerative materials.

The growth rate of PDRN skincare products is rapid, with prices falling into the mass-market range, transitioning from niche to daily use for the public. Leveraging social media for awareness and with the synergistic development of aesthetic medicine and skincare, its prospects are broad. Overseas PDRN development maintains good momentum, while domestic companies are poised for action, with new cosmetic products emerging and medical device approvals imminent.

Core Insights from the Report

PDRN (Polydeoxyribonucleotide) possesses reparative and anti-inflammatory properties. Since its application by humans in the 15th century, its efficacy, extraction methods, and scope of use have continuously evolved and expanded. PDRN is a mixture of short-chain DNA fragments composed of deoxyribonucleotides with strong hydrophilicity. After centuries of development, PDRN has progressed from discovery to medical use, and further into areas like aesthetic medicine and skincare: in the 15th century, European fishermen discovered salmon milt could promote healing; it was approved as a drug in the 1980s and 1990s; post-2000, it ignited the aesthetic medicine market in South Korea, and from 2010–2024, imported products dominated the Chinese market, prompting domestic companies to initiate import substitution; in 2025, synthetic biology-derived PDRN emerged, leading to industry standardization and its popularization in the skincare field. PDRN is another rising star in the field of regenerative materials.

Dual Development Pathways

The regenerative and reparative material PDRN is entering a core track. The global aesthetic medicine industry is shifting towards non-surgical and minimally invasive treatments, with consumers moving from pursuing immediate results to long-term skin health. Leveraging its reparative, anti-inflammatory, and collagen-boosting effects, PDRN fits scenarios like post-procedure recovery and sensitive skin care, forming a new consumption trend. The growth rate of China's PDRN aesthetic injection market far exceeds that of similar products, with an extremely high compound annual growth rate projected from 2023–2028. It is expected to form a tripartite landscape alongside microspheres and collagen.

The growth rate of PDRN skincare products is rapid, with prices falling into the mass-market range, transitioning from niche to daily use for the public. Leveraging social media for awareness and with the synergistic development of aesthetic medicine and skincare, its prospects are broad.

Global PDRN Deployment Momentum

The wave of PDRN deployment domestically and internationally has arrived, with domestic companies taking the lead in raw materials, further boosting the heat in beauty and personal care.

1) Overseas PDRN development maintains good momentum, with long-established Korean and European enterprises. Among them, Korea's Pharma Research, with PDRN/PN regenerative technology at its core, started from pharmaceutical consulting and gradually grew into a comprehensive regenerative medical group covering pharmaceuticals, medical devices, and cosmetics. Its core brand, Rejuran, based on PDRN/PN ingredients, has a differentiated product series layout. The basic Rejuran line focuses on temporary improvement of adult facial wrinkles, while the advanced Rejuran HB plus innovatively combines cross-linked hyaluronic acid and lidocaine for physical repair via subcutaneous injection. In the application and popularization of cosmetic ingredients, international companies represented by the L'Oréal Group have begun incorporating and promoting PDRN concepts in flagship products of brands like Lancôme and L'Oréal Paris.

2) Domestic companies are poised for action, with new cosmetic products emerging and medical device approvals imminent. Regarding raw materials and skincare, Bloomage Biotech leads domestic companies, having built a comprehensive patent portfolio from raw material preparation to end-application around PDRN, forming a clear matrix of technological barriers. Under Shanghai Jahwa United Co., Ltd., the brands KanS and Juguangbai are making strong moves, creating PDRN Aqua Glow Sticks/Special Care Ampoules, and the Juguangbai Collagen Salmon Aqua Glow Ampoule Essence. Proya strikes with its Source Power + Ruby series, utilizing PDRN to focus on repair and firming effects. Guangdong Songfa Plastic Industry Co., Ltd. leads in plant cell intelligent manufacturing platforms and PDRN-related extraction technologies. Marubi Biotechnology Co., Ltd. promotes the dual-core concept of PDRN + Collagen, with its PDRN product topping the new mask product chart. In medical devices, Lepu Medical Technology (Beijing) Co., Ltd. currently has its main product under development being Sodium Hyaluronate Composite Solution for Injection (PDRN), which is in the post-supplement correction stage, with registration expected to be submitted in 2026.

Key Investment Recommendations

The report highlights recommendations for companies active in the PDRN space across three fronts: raw materials, skincare, and medical devices.

Key recommendations include: 1) Bloomage Biotech, which is active in PDRN across raw materials, skincare, and medical devices; 2) Shanghai Jahwa United Co., Ltd., which owns the Juguangbai brand with PDRN as a core highlight and whose KanS brand is also actively launching new PDRN products; 3) Proya, which focuses on deploying new PDRN products within its flagship Source Power and Ruby series; 4) Forest Cabin, which extracts PDRN from plants and has successfully launched featured products like anti-wrinkle neck masks and eye masks; 5) Botanee Bio-Technology Co., Ltd., whose high-end brand Aoxmed incorporates PDRN; 6) Guangdong Songfa Plastic Industry Co., Ltd., which leads in plant cell intelligent manufacturing platforms and PDRN-related extraction technologies; 7) Marubi Biotechnology Co., Ltd. and Freda, whose PDRN products are selling well online.

8) Suggested for attention: Lepu Medical Technology (Beijing) Co., Ltd., a leader in domestic PDRN medical device R&D, with its Sodium Hyaluronate Composite Solution for Injection (PDRN) expected to submit for registration in 2026.

Risk Factors to Consider

Key risks include heightened macroeconomic uncertainty; shifts in market demand; intensifying industry competition; tightening regulations testing corporate compliance capabilities; and public sentiment risks.